<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540043</url>
  </required_header>
  <id_info>
    <org_study_id>DV16-PUR0110-C001</org_study_id>
    <nct_id>NCT03540043</nct_id>
  </id_info>
  <brief_title>Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis</brief_title>
  <official_title>4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PurGenesis Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PurGenesis Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, multicenter, double-blind, placebo control study evaluating the safety and&#xD;
      efficacy of Thykamine in adult patient suffering of mild-to-moderate Atopic Dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      4-week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and&#xD;
      Efficacy Study of Three Concentrations (0.05%, 0.1% and 0.25%) of PUR 0110 (Thykamine™) Cream&#xD;
      Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Actual">June 3, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Parallel-Group, Placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment were packaged in identical jars. Eligible patients will be randomized in a 1:1:1:1 ratio to receive either one of 3 concentrations of PUR 0110 cream (0.05%, 0.1% and 0.25%) or vehicle (placebo).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as per investigator global assessment (IGA)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Efficacy as per investigator global assessment (IGA) of clear (0), almost clear (1) at Day 29 and with a decrease from baseline in IGA of at least 2 grades at Day 29.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs) (systemic and local)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Incidence and severity of adverse events (AEs) (systemic and local) as a measure of safety and tolerability of treatment for up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Atopic Dermatitis (AD) score</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to Day 29 in the 4 individual signs/symptoms score of AD including: erythema, induration/papulation, excoriation and lichenification measured in the target lesion on a 4-point scale defined as : 0 = None; 1=Mild; 2=Moderate and 3=Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pruritus</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to Day 29 in pruritus, measured on a 4-point scale defined as : 0=None; 1=Mild; 2=Moderate and 3=Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with change in Investigator Global Assessment (IGA)</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>• Proportion of patients with an IGA of clear (0), almost clear (1) and with a decrease from baseline in IGA of at least 2 grades at intermediate visits (Days 7, 14 and 21). Scores being defined as : 0=Clear ; 1=Almost Clear; 2:=Mild disease; 3=Moderate disease and 4 = Severe disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to Day 29 in Eczema Area and Severity Index (EASI).Four body regions are considered separately and include: Head and neck; Trunk ; Upper extremities; Lower extremities (including the buttocks).Extent of Eczema in these regions is being scored as follow : 0 = 0% involvement; 1= 1-9%; 2 = 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89% and 6= 90-100%. Severity of erythema, edema/papulation, excoriation and lichenification , for each region is scaled as : 0=none; 1= mild; 2= moderate and 3= severe. Final EASI score is the sum of the 4 region scores and ranges from 0-72.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EASI improvement</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Proportion of patients with at least a 50% and 75% improvement in EASI (EASI50) at Day 29 as compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in body surface area (BSA).</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to Day 29 in body surface area (BSA) affected by disease.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Dermatology Life Quality Index (DLQI).</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to Day 29 in Dermatology Life Quality Index (DLQI) evaluating the impact on Quality of life scale : Very much ; A lot; a little or Not at all.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Patient-Oriented Eczema Measure (POEM).</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Change from baseline to Day 29 in Patient-Oriented Eczema Measure (POEM) investigating the number of days patients have been subjected, due to eczema, to itchy skin, sleep disturbance; skin bleeding; skin weeping; skin craked; skin flaking and skin dryness. Scale defined as : 0 = no days; 1= 1-2 days; 2= 3-4 days; 3= 5-6 days; 4 = everyday</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Atopic Dermatitis Eczema</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0110 (Thykamine) 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of PUR0110 (Thykamine) 0.05%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0110 (Thykamine) 0.10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of PUR0110 (Thykamine) 0.10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PUR0110 (Thykamine) 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of PUR0110 (Thykamine) 0.25%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Placebo</intervention_name>
    <description>Botanical Drug Phase 2 clinical study</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of PUR0110 (Thykamine) 0.05%</intervention_name>
    <description>Botanical Drug Phase 2 clinical study</description>
    <arm_group_label>PUR0110 (Thykamine) 0.05%</arm_group_label>
    <other_name>Active arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of PUR0110 (Thykamine) 0.1%</intervention_name>
    <description>Botanical Drug Phase 2 clinical study</description>
    <arm_group_label>PUR0110 (Thykamine) 0.10%</arm_group_label>
    <other_name>Active arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of PUR0110 (Thykamine) 0.25%</intervention_name>
    <description>Botanical Drug Phase 2 clinical study</description>
    <arm_group_label>PUR0110 (Thykamine) 0.25%</arm_group_label>
    <other_name>Active arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        The patient must meet all the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Male or female patients, aged 18 years or older at the screening visit.&#xD;
&#xD;
          2. Patients with diagnosis of AD for at least 6 months prior to Day 0 visit as defined by&#xD;
             the criteria of Hanifin and Rajka (Acta Derm Venereol. 1980).&#xD;
&#xD;
          3. Patients with BSA ≥ 1 % and ≤ 15% at Day 0 (excluding palms, soles and scalp).&#xD;
&#xD;
          4. Patients with IGA score of 2 to 3 (mild-to-moderate) at Day 0.&#xD;
&#xD;
          5. Female patients of childbearing potential must have a negative pregnancy test (serum&#xD;
             Beta-hCG) at the screening visit - unless they are surgically sterile (hysterectomy,&#xD;
             bilateral oophorectomy or tubal ligation), in a menopausal state for at least a year,&#xD;
             clinically diagnosed infertile, or have a same-sex partner or are abstinent.&#xD;
&#xD;
          6. In addition, females of childbearing potential or a male patient with a female partner&#xD;
             must be willing to use an effective contraceptive method for at least 30 days (12&#xD;
             weeks for hormonal contraceptives) before Day 0 and at least 1 month after the last&#xD;
             study drug administration. Effective contraceptive methods include:&#xD;
&#xD;
               -  Barrier methods such as condom, sponge or diaphragm combined with spermicide in&#xD;
                  foam, gel or cream;&#xD;
&#xD;
               -  Hormonal contraception (oral, intramuscular, implant or transdermal) which&#xD;
                  include Depo Provera, Evra and Nuvaring; and&#xD;
&#xD;
               -  Intrauterine device (IUD).&#xD;
&#xD;
          7. Patients must be capable of giving informed consent and the consent must be obtained&#xD;
             prior to any study related procedures.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Patient with BSA &gt; 15% (excluding palms, soles and scalp).&#xD;
&#xD;
          2. Female who is pregnant or lactating or wishes to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          3. Patient with a history of any confounding inflammatory skin diseases or any other skin&#xD;
             disease, e.g., psoriasis, rosacea, erythroderma or ichthyosis, that could impair&#xD;
             his/her safety during the study or interfere with the evaluation of AD.&#xD;
&#xD;
          4. Patient with spontaneously improving or rapidly deteriorating AD.&#xD;
&#xD;
          5. Patient with active allergic contact dermatitis or other non-atopic forms of&#xD;
             dermatitis.&#xD;
&#xD;
          6. Patient with active cutaneous bacterial or viral or fungal infection in any treatment&#xD;
             area at baseline (e.g., clinically infected AD).&#xD;
&#xD;
          7. Patient with acute infections.&#xD;
&#xD;
          8. Patient with a history or presence of Netherton's syndrome, immunological deficiencies&#xD;
             or diseases, diabetes, malignancy, psychological disorders, serious active or&#xD;
             recurrent infection, clinically significant severe renal insufficiency or severe&#xD;
             hepatic disorders - which might cause this study to be detrimental to the patient or&#xD;
             that may confound the study results or interfere significantly with the patient's&#xD;
             participation in the study.&#xD;
&#xD;
          9. Patient with bleeding disorders.&#xD;
&#xD;
         10. Patient with known seropositivity for the human immunodeficiency virus or evidence of&#xD;
             active hepatitis B or C.&#xD;
&#xD;
         11. Patient has an unstable or serious medical condition, as defined by the investigator,&#xD;
             which might cause this study to be detrimental to the patient or that may confound the&#xD;
             study results or interfere significantly with the patient's participation in the&#xD;
             study.&#xD;
&#xD;
         12. Patient has a history of alcoholism or drug abuse within 12 months prior to Day 0.&#xD;
&#xD;
         13. Patient with known allergy, or history of allergic reaction, or hypersensitivity to&#xD;
             spinach, spinach tablet, spinach powder or spinach extract; to mushrooms; or any&#xD;
             ingredients present in PUR 0110.&#xD;
&#xD;
         14. Patient with a history of severe food allergies.&#xD;
&#xD;
         15. Patient with sunburn, extensive scarring, or pigmented lesion(s) in any treatment area&#xD;
             at baseline (Day 0), which would interfere with evaluations.&#xD;
&#xD;
         16. Use within 4 weeks prior to baseline (Day 0) of oral or intravenous corticosteroids,&#xD;
             UVA/UVB therapy, PUVA (psoralen plus ultraviolet A) therapy, tanning booths,&#xD;
             non-prescription UV light sources, immunomodulators or immunosuppressive therapies,&#xD;
             interferon, or cytotoxic drugs.&#xD;
&#xD;
         17. Use within 2 weeks of baseline (Day 0) of systemic antibiotics, calcipotriene or other&#xD;
             vitamin D preparations, or retinoids.&#xD;
&#xD;
         18. Use within 2 weeks of baseline (Day 0) of oral natural health products or vitamins&#xD;
             containing lutein.&#xD;
&#xD;
         19. Use within 1 week prior to baseline (Day 0) of antihistamines, topical antibiotics,&#xD;
             topical corticosteroids, topical calcineurin inhibitors or other topical drug products&#xD;
             used for treating AD. Inhaled corticosteroids for stable medical conditions are&#xD;
             allowed.&#xD;
&#xD;
         20. Use within 24 hours prior to baseline (Day 0) of any topical product (e.g.,&#xD;
             sunscreens, lotions, creams) in the areas to be treated, except for bland emollient&#xD;
             (moisturizer).&#xD;
&#xD;
         21. Use of an investigational agent within 4 weeks or 5 half-lives prior to Day 0&#xD;
             (whichever is longer).&#xD;
&#xD;
         22. Patient not willing to minimize or avoid natural and artificial sunlight exposure&#xD;
             during treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Poulin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre de Recherche Dernatologique du Quebec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Jing Loo, MD</last_name>
    <role>Study Director</role>
    <affiliation>DermEffects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research Inc. (Burlington North)</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEffects</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research Inc. (Toronto)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermEdge Research imc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontation</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q&amp;T Research Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Isabelle Delorme Inc.</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B 5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David Gratton Dermatologue Inc.</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Saint-Louis</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild moderate atopic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

